Dr Lalchandani Labs Limited
BSE:541299 Voorraadrapport
Marktkapitalisatie: ₹78.0m
Dr Lalchandani Labs Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6 Dr Lalchandani Labs heeft een totaal eigen vermogen van ₹96.9M en een totale schuld van ₹36.3M, wat de schuld-eigenvermogensverhouding op 37.5% brengt. De totale activa en totale passiva bedragen respectievelijk ₹153.7M en ₹56.8M.
Belangrijke informatie
37.5%
Verhouding schuld/eigen vermogen
Rente dekkingsratio n/a Contant ₹28.21m Aandelen ₹96.92m Totaal verplichtingen ₹56.82m Totaal activa ₹153.73m
Recente financiële gezondheidsupdates
Toon alle updates
Chairman & MD recently bought ₹317k worth of stock Oct 30
First half 2025 earnings released: EPS: ₹0.35 (vs ₹0.20 loss in 1H 2024) Oct 17
Investor sentiment improves as stock rises 20% Oct 14
Dr Lalchandani Labs Limited to Report Q2, 2025 Results on Oct 14, 2024 Oct 09
Dr Lalchandani Labs Limited to Report First Half, 2025 Results on Oct 14, 2024 Oct 08
Dr Lalchandani Labs Limited, Annual General Meeting, Sep 30, 2024 Sep 12
Full year 2024 earnings released: EPS: ₹1.43 (vs ₹3.61 loss in FY 2023) Sep 08
New minor risk - Financial data availability Jun 01
Dr Lalchandani Labs Limited to Report Second Half, 2024 Results on May 30, 2024 May 20
Dr Lalchandani Labs Limited Approves Appointment of Namita Anand as Company Secretary and Compliance Officer May 03
Dr Lalchandani Labs Limited Announces the Resignation of Archana R Jha as Company Secretary and Compliance Officer Feb 03
Less than half of directors are independent Dec 08
Dr Lalchandani Labs Limited Announces Resignation of Monika Joshi as Company Secretary and Compliance Officer Nov 29
Dr Lalchandani Labs Limited Announces Resignation of Monika Joshi as Company Secretary and Compliance Officer Nov 28
First half 2024 earnings released: ₹0.20 loss per share (vs ₹2.24 loss in 1H 2023) Nov 20
New major risk - Financial position Nov 17
Less than half of directors are independent Nov 01
Less than half of directors are independent Sep 25
Dr Lalchandani Labs Limited Announces Resignation of Archana Jha from the Office of Company Secretary Sep 24
Dr Lalchandani Labs Limited, Annual General Meeting, Sep 30, 2023 Sep 09
Dr Lalchandani Labs Limited Appoints Monika Joshi as Company Secretary and Compliance Officer, Effective August 27, 2023 Aug 26
Less than half of directors are independent Aug 21
Less than half of directors are independent Jul 14
New major risk - Revenue and earnings growth Jun 21
Full year 2023 earnings released: ₹3.61 loss per share (vs ₹2.15 profit in FY 2022) Jun 20
Less than half of directors are independent May 25
Dr Lalchandani Labs Limited to Report Fiscal Year 2023 Results on May 30, 2023 May 25
Less than half of directors are independent May 04
Less than half of directors are independent Mar 15
Dr Lalchandani Labs Limited Announces Management Changes Feb 16
Dr Lalchandani Labs Limited Appoints Archana Jha as Company Secretary & Compliance Officer Feb 06
First half 2023 earnings released Nov 20
Less than half of directors are independent Nov 16
Dr Lalchandani Labs Limited to Report First Half, 2023 Results on Nov 14, 2022 Nov 12
Investor sentiment improved over the past week Nov 09
Investor sentiment improved over the past week Oct 19
Full year 2022 earnings released: EPS: ₹2.15 (vs ₹2.33 in FY 2021) Sep 14
Dr Lalchandani Labs Limited, Annual General Meeting, Sep 30, 2022 Sep 09
Less than half of directors are independent Aug 30
Dr Lalchandani Labs Limited Announces Resignation of CS Swati Poddar as Company Secretary and Compliance Officer Aug 10
Dr Lalchandani Labs Limited Resumes in Full Capacity At the Lab in Punjabi Bagh May 31
Investor sentiment deteriorated over the past week May 31
Dr Lalchandani Labs Limited to Report Fiscal Year 2022 Results on May 30, 2022 May 24
Investor sentiment deteriorated over the past week May 10
Less than half of directors are independent Apr 28
Investor sentiment deteriorated over the past week Apr 04
Investor sentiment deteriorated over the past week Dec 17
Investor sentiment improved over the past week Nov 24
Investor sentiment deteriorated over the past week Aug 23
Full year 2021 earnings released: EPS ₹2.33 (vs ₹1.09 in FY 2020) Jul 14
Investor sentiment improved over the past week Jul 11
Investor sentiment deteriorated over the past week Jun 25
Investor sentiment improved over the past week May 18
Investor sentiment improved over the past week Apr 15
Investor sentiment improved over the past week Mar 31
Investor sentiment deteriorated over the past week Feb 24
New 90-day low: ₹13.00 Feb 15
Dr Lalchandani Labs Limited to Report First Half, 2021 Results on Nov 13, 2020 Nov 07
Market pulls back on stock over the past week Oct 15
New 90-day high: ₹12.10 Oct 06
Full year earnings released - EPS ₹1.09 Sep 11
Dr Lalchandani Labs Limited to Report Fiscal Year 2020 Results on Jun 30, 2020 Jun 28
Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( ₹102.2M ) 541299 } overtreffen de korte termijn passiva ( ₹52.6M ).
Langlopende schulden: De kortetermijnactiva 541299 ( ₹102.2M ) overtreffen de langetermijnschulden ( ₹4.2M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 8.3% ) 541299 wordt als voldoende beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van 541299 is de afgelopen 5 jaar gestegen van 22.2% naar 37.5%.
Schuldendekking: De schuld van 541299 wordt goed gedekt door de operationele kasstroom ( 78.9% ).
Rentedekking: Er zijn onvoldoende gegevens om te bepalen of de rentebetalingen van 541299 op haar schulden goed worden gedekt door EBIT .
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}